Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients

Drug Safety

Volumn 30, Issue 1, 2007, Pages 71-80

  Indermitte, Jörg ^a   Burkolter, Sabine ^a   Drewe, Jürgen ^a,b   Krähenbühl, Stephan ^a,b   Hersberger, Kurt E ^a,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Institute for Clinical Pharmacy   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMINOCAPROIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; HEPARIN; HERBACEOUS AGENT; LITHIUM; LOOP DIURETIC AGENT; LYSINE; MANNITOL; METYRAPONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G POTASSIUM; PENTAMIDINE; POTASSIUM; POTASSIUM CHLORIDE; POTASSIUM SPARING DIURETIC AGENT; SOMATOSTATIN; SPIRONOLACTONE; SUXAMETHONIUM; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SWITZERLAND;

EID: 33846071937     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730010-00007     Document Type: Article

References (22)

1. Schaefer TJ, Wolford RW. Disorders of potassium. Emerg Med Clin North Am 2005 Aug; 23 (3): 723-47
2. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000 Sep; 109 (4): 307-14
3. Acker CG, Johnson JP, Palevsky PM, et al. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998 Apr; 158 (8): 917-24
4. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004 Aug; 351 (6): 585-92
5. Evans KJ, Greenberg A. Hyperkalemia: a review. J Intensive Care Med 2005 Sep-Oct; 20 (5): 272-90
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep; 341 (10): 709-17
7. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 Aug; 351 (6): 543-51
8. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003 Jan; 41 (2): 211-4
9. Juurlink DN, Hansten PD. Drug safety in patients with heart failure. Arch Intern Med 2005 Jan; 165 (1): 118
10. Wrenger E, Muller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003 Oct; 327 (7407): 147-9
11. Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 2002 Sep; 90 (6): 663-5
12. Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management, 2005 edition. Edmonds (WA): H&H Publications, 2004
13. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003 Mar; 58 (11): 773-8
14. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28 (3): 263-75
15. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 2005 Jun; 30 (3): 233-9
16. Stevens MS, Dunlay RW. Hyperkalemia in hospitalized patients. Int Urol Nephrol 2000; 32 (2): 177-80
17. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
18. Lawson DH. Adverse reactions to potassium chloride. Q J Med 1974; 43 (171): 433-40
19. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003 Sep; 18 (9): 1814-9
20. Clayton JA, Rodgers S, Blakey J, et al. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2006 Jan; 61 (1): 87-95
21. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function - Measured and estimated glomerular filtration rate. N Engl J Med 2006 Jun; 354 (23): 2473-83
22. Schiff GD, Aggarwal HC, Kumar S, et al. Prescribing potassium despite hyperkalemia: medication errors uncovered by linking laboratory and pharmacy information systems. Am J Med 2000 Oct; 109 (6): 494-7